The case for & against
Bull & Bear analysis
Bullish
iRadimed Corporation (NASDAQ: IRMD) is a leading player in the medical device industry, specializing in innovative infusion pumps and patient monitoring systems, primarily focusing on MRI-compatible technologies. The company is positioned within the healthcare sector, with its products designed to enhance patient safety and operational efficiency in hospitals. As the healthcare environment increasingly trends toward advanced technology solutions, iRadimed stands to benefit from both increasing patient numbers and the need for upgraded equipment.
Bull says
- ↑Q1 2026 revenue reached $22 M, a 13% YoY gain on 3870 pump ramp
- ↑Gross margin of 77% reflects strong profitability and cost control
- ↑Consumables for the 3870 system to drive recurring revenue growth
- ↑Low leverage position provides financial flexibility for scaling
- ↑Analyst consensus “Buy” and ~22% undervaluation support upside
- ↑Positive momentum and growth factors bolster long-term outlook
Bear says
- ↓Negative earnings yield may indicate valuation stretched without growth
- ↓Short interest remains elevated, reflecting investor skepticism
- ↓Guidance of $20–21 M for Q2 may show a legacy pump revenue dip
- ↓Higher interest rates could constrain hospital purchasing budgets
- ↓Reliance on a single product rollout exposes saturation risk
- ↓Negative factor revisions and size concerns temper the outlook
Investment themes with IRMD
Medical Devices↑ +0.12%
Devices and instruments for medical treatment
ISRG · ABT · SYK
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 05-29-2026neutral
Transcript signals
Bull points
- For the first quarter of 2025, we achieved revenue of $19.5 million, which is an 11% increase over the same period last year.
- Gross profit came in at 76.1%, with earnings very strong as well, with GAAP diluted earnings per share increasing 16% from Q1 of 2024.
- Performance in the quarter was led by pump shipments, with bookings of our 3860 MRI IV pump continuing to excel in Q1.
Bear points
- If even in a horrible worst case, if Chinese tariffs should remain at 145%, our 3% cost of such high tariff parts goes to 4.35%.
- there is the threat that we already see with certain suppliers raising their pricing by using tariffs more as an excuse to gouge.
- Free cash flow, a non-GAAP measure, was $0.4 million, down from $3.4 million in Q1 2024 due to $3.9 million in capital expenditures in the quarter, of which $3.5 million was for the new facility.
Read full transcript analysis ›